FDMT
4D Molecular Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$11.09+0.91%
Price as of Jul 20, 2026
FDMT profitability
4D Molecular Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -12.4%
- EBITDA margin
- -185.2%
- EBIT margin
- -203.5%
- Net margin
- -182.3%
- Free cash flow margin
- -147.4%
Returns
- Return on equity
- -35.6%
- Return on assets
- -31.4%
- Return on invested capital
- -38.0%
- Asset turnover
- 0.16x
Cash efficiency
- Cash from operations
- -$129.4M
- Cash per share
- $7.48
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.